Solid Biosciences (SLDB) Share-based Compensation (2017 - 2026)

Solid Biosciences has reported Share-based Compensation for 10 years, with the latest figure at $5.2 million in Q1 2026.

• Quarterly Share-based Compensation rose 54.21% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.7 million (up 52.87% YoY) and the FY2025 annual result came in at $16.9 million, up 60.79% from the prior year.
• Share-based Compensation declined to $5.2 million in Q1 2026 per SLDB's latest filing, from $6.5 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $6.5 million in Q4 2025 and troughed at -$21.6 million in Q4 2022.
• A 5-year average of $1.4 million and a median of $2.4 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation sank 732.18% in 2022, then soared 107.39% in 2025.
• Over 5 years, Share-based Compensation stood at -$21.6 million in 2022, then jumped by 107.53% to $1.6 million in 2023, then jumped by 135.14% to $3.8 million in 2024, then soared by 70.11% to $6.5 million in 2025, then fell by 20.74% to $5.2 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $5.2 million, $6.5 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.